Matching articles for "Antidepressants"

In Brief: Off-Label Amitriptyline for Insomnia

   
The Medical Letter on Drugs and Therapeutics • March 20, 2023;  (Issue 1672)
In our article on Drugs for Chronic Insomnia, we said there is little evidence that antidepressants such as trazodone, mirtazapine, or amitriptyline are effective in treating insomnia not associated with...
In our article on Drugs for Chronic Insomnia, we said there is little evidence that antidepressants such as trazodone, mirtazapine, or amitriptyline are effective in treating insomnia not associated with depression. We received a comment from a reader who has prescribed the tricyclic antidepressant amitriptyline for insomnia, particularly for patients with headache disorders, and finds that most patients are satisfied with the treatment.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):48 | Show Full IntroductionHide Full Introduction

Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis

   
The Medical Letter on Drugs and Therapeutics • February 6, 2023;  (Issue 1669)
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) for treatment of eosinophilic esophagitis (EoE) in patients ≥12...
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) for treatment of eosinophilic esophagitis (EoE) in patients ≥12 years old who weigh ≥40 kg and treatment of prurigo nodularis in adults. Dupilumab is the first drug to be approved in the US for each of these indications. It is also FDA-approved for treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):18-20 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • January 9, 2023;  (Issue 1667)
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 | Show Full IntroductionHide Full Introduction

Dextromethorphan/Bupropion (Auvelity) for Depression

   
The Medical Letter on Drugs and Therapeutics • December 26, 2022;  (Issue 1666)
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion (Auvelity – Axsome) for treatment of major depressive disorder (MDD) in...
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion (Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):201-3 | Show Full IntroductionHide Full Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • August 22, 2022;  (Issue 1657)
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 | Show Full IntroductionHide Full Introduction

Lumateperone (Caplyta) for Bipolar Depression

   
The Medical Letter on Drugs and Therapeutics • August 8, 2022;  (Issue 1656)
The oral second-generation antipsychotic drug lumateperone (Caplyta – Intra-Cellular Therapies), which was approved by the FDA in 2020 for treatment of schizophrenia, is now approved for use...
The oral second-generation antipsychotic drug lumateperone (Caplyta – Intra-Cellular Therapies), which was approved by the FDA in 2020 for treatment of schizophrenia, is now approved for use as monotherapy or as an adjunct to lithium or valproate for treatment of depressive episodes associated with bipolar I or II disorder in adults.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):126-8 | Show Full IntroductionHide Full Introduction

Daridorexant (Quviviq) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • July 11, 2022;  (Issue 1654)
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin...
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):107-10 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • October 5, 2020;  (Issue 1608)
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2020 Oct 5;62(1608):153-60 | Show Full IntroductionHide Full Introduction

A New Indication for Esketamine Nasal Spray (Spravato)

   
The Medical Letter on Drugs and Therapeutics • September 21, 2020;  (Issue 1607)
Esketamine (Spravato – Janssen), an intranasal N-methyl-D-aspartate (NMDA) receptor antagonist that was previously approved by the FDA for treatmentresistant depression,1 has now been approved...
Esketamine (Spravato – Janssen), an intranasal N-methyl-D-aspartate (NMDA) receptor antagonist that was previously approved by the FDA for treatmentresistant depression,1 has now been approved for treatment of depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. Esketamine is the S-enantiomer of the anesthetic ketamine (Ketalar, and generics). It is the first drug to be approved for this indication. Most clinical trials of antidepressants have excluded patients with acute suicidal ideation.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):151 | Show Full IntroductionHide Full Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • August 10, 2020;  (Issue 1604)
The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia,...
The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and dysuria, and increase the risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep. Hormone therapy is the most effective treatment for both genitourinary and vasomotor symptoms.
Med Lett Drugs Ther. 2020 Aug 10;62(1604):124-8 | Show Full IntroductionHide Full Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • March 23, 2020;  (Issue 1594)
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant...
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Alterations in the microbiome, stress responses, sensory and motor function of the gut, and host genetic factors may be contributing factors. Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Med Lett Drugs Ther. 2020 Mar 23;62(1594):41-8 | Show Full IntroductionHide Full Introduction

Drugs for Depression

   
The Medical Letter on Drugs and Therapeutics • February 24, 2020;  (Issue 1592)
Complete remission of symptoms is the goal of treatment for major depressive disorder; a partial response is associated with an increased risk of relapse. Improvement in symptoms can occur within the first...
Complete remission of symptoms is the goal of treatment for major depressive disorder; a partial response is associated with an increased risk of relapse. Improvement in symptoms can occur within the first two weeks of treatment with an antidepressant, but it may take 4-8 weeks to achieve a substantial benefit. Following successful treatment of a first major depressive episode, antidepressant treatment should be continued at the same dose for at least 4-9 months to consolidate recovery. In patients with recurrent depressive episodes, long-term maintenance treatment can reduce the risk of relapse.
Med Lett Drugs Ther. 2020 Feb 24;62(1592):25-32 | Show Full IntroductionHide Full Introduction

Drugs for Anxiety Disorders

   
The Medical Letter on Drugs and Therapeutics • August 12, 2019;  (Issue 1578)
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive...
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy. Obsessive-compulsive disorder and posttraumatic stress disorder are now considered separate entities in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); they can also be treated with CBT and many of the same drugs.
Med Lett Drugs Ther. 2019 Aug 12;61(1578):121-6 | Show Full IntroductionHide Full Introduction

Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression

   
The Medical Letter on Drugs and Therapeutics • April 8, 2019;  (Issue 1569)
The FDA has approved esketamine (Spravato – Janssen), an N-methyl-D-aspartate (NMDA) receptor antagonist, for intranasal treatment (in conjunction with an oral antidepressant) of adults with...
The FDA has approved esketamine (Spravato – Janssen), an N-methyl-D-aspartate (NMDA) receptor antagonist, for intranasal treatment (in conjunction with an oral antidepressant) of adults with treatment-resistant depression (TRD). This is the first FDA approval for esketamine, which is the S-enantiomer of the intravenous anesthetic ketamine (Ketalar, and generics). In recent years, IV ketamine has been increasingly used (off-label) for treatment of TRD.
Med Lett Drugs Ther. 2019 Apr 8;61(1569):54-6 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • December 17, 2018;  (Issue 1562)
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Med Lett Drugs Ther. 2018 Dec 17;60(1562):201-5 | Show Full IntroductionHide Full Introduction

Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • November 5, 2018;  (Issue 1559)
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in...
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.
Med Lett Drugs Ther. 2018 Nov 5;60(1559):177-80 | Show Full IntroductionHide Full Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • April 9, 2018;  (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Med Lett Drugs Ther. 2018 Apr 9;60(1544):57-64 | Show Full IntroductionHide Full Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • February 12, 2018;  (Issue 1540)
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Med Lett Drugs Ther. 2018 Feb 12;60(1540):24-32 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • November 20, 2017;  (Issue 1534)
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Med Lett Drugs Ther. 2017 Nov 20;59(1534):187-94 | Show Full IntroductionHide Full Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • September 25, 2017;  (Issue 1530)
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2017 Sep 25;59(1530):155-61 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • February 13, 2017;  (Issue 1514)
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use...
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
Med Lett Drugs Ther. 2017 Feb 13;59(1514):27-32 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • February 13, 2017;  (Issue 1514)
...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2017 Feb 13;59(1514):e31-2 | Show Full IntroductionHide Full Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • September 26, 2016;  (Issue 1504)
Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as...
Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Med Lett Drugs Ther. 2016 Sep 26;58(1504):121-6 | Show Full IntroductionHide Full Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • August 15, 2016;  (Issue 1501)
Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the...
Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the drugs and dosages recommended here have not been approved by the FDA for use in bipolar disorder.
Med Lett Drugs Ther. 2016 Aug 15;58(1501):103-6 | Show Full IntroductionHide Full Introduction

Drugs for Depression

   
The Medical Letter on Drugs and Therapeutics • July 4, 2016;  (Issue 1498)
Complete remission of symptoms is the goal of antidepressant therapy; partial response is associated with an increased risk of relapse. Improvement can occur within the first two weeks of drug therapy, but...
Complete remission of symptoms is the goal of antidepressant therapy; partial response is associated with an increased risk of relapse. Improvement can occur within the first two weeks of drug therapy, but it may take 4-8 weeks to achieve a substantial benefit. Fewer than 50% of patients with depression respond to first-line pharmacotherapy, and the rate of response decreases with each subsequent drug trial. Following remission after a first episode of depression, many experts recommend continuing antidepressant treatment at the same dose for at least 6-12 months to consolidate recovery. For patients with recurrent depressive episodes, long-term maintenance therapy can reduce the risk of recurrence.
Med Lett Drugs Ther. 2016 Jul 4;58(1498):85-90 | Show Full IntroductionHide Full Introduction

Brexpiprazole (Rexulti) for Schizophrenia and Depression

   
The Medical Letter on Drugs and Therapeutics • August 17, 2015;  (Issue 1475)
The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole (Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of...
The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole (Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder (MDD). Aripiprazole (Abilify), a structurally similar second-generation antipsychotic also comarketed by Otsuka (with BMS), recently became available generically.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):116-8 | Show Full IntroductionHide Full Introduction

Drugs for Insomnia

   
The Medical Letter on Drugs and Therapeutics • July 6, 2015;  (Issue 1472)
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not...
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):95-8 | Show Full IntroductionHide Full Introduction

Suvorexant (Belsomra) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • March 2, 2015;  (Issue 1463)
The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance...
The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31 | Show Full IntroductionHide Full Introduction

Diet, Drugs, and Surgery for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • February 16, 2015;  (Issue 1462)
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. Losing even a small amount of weight and increasing physical activity...
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing weight, but long-term failure rates are high. Several drugs have been approved by the FDA for weight reduction, but adherence is poor, adverse effects are common, and patients usually regain the lost weight when the drug is stopped. Bariatric surgery can produce substantial weight loss and significantly reduce obesity-related comorbidities; long-term data on its safety are encouraging, but still limited. Guidelines for the management of overweight or obese adults have recently been published.
Med Lett Drugs Ther. 2015 Feb 16;57(1462):21-8 | Show Full IntroductionHide Full Introduction

In Brief: Khedezla - A New Brand of Desvenlafaxine

   
The Medical Letter on Drugs and Therapeutics • January 6, 2014;  (Issue 1433)
The FDA has approved the marketing of another extended-release brand-name formulation of the serotonin and norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (Khedezla – Par/Osmotica) for treatment of...
The FDA has approved the marketing of another extended-release brand-name formulation of the serotonin and norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (Khedezla – Par/Osmotica) for treatment of depression. It is the third extended-release formulation of desvenlafaxine to become available in the US. Khedezla was approved using a 505(b)(2) application, a new drug application (NDA) that relies upon the FDA's findings of safety and/or effectiveness for a previously approved drug.

Khedezla does not appear to offer any advantage over the other extended-release formulations of desvenlafaxine. There is no evidence that any formulation of desvenlafaxine is more effective for treatment of depression than other SNRIs or any SSRI, which are available in less expensive generic formulations.1

1. Drugs for psychiatric disorders. Treat Guidel Med Lett 2013; 11:53.

Download complete U.S. English article

Med Lett Drugs Ther. 2014 Jan 6;56(1433):4 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • December 1, 2013;  (Issue 136)
Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed...
Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.
Treat Guidel Med Lett. 2013 Dec;11(136):107-12 | Show Full IntroductionHide Full Introduction

Vortioxetine (Trintellix) for Depression

   
The Medical Letter on Drugs and Therapeutics • November 25, 2013;  (Issue 1430)
The FDA has approved vortioxetine (vor" tye ox' e teen; Trintellix – Takeda/Lundbeck), a new serotonergic drug, for treatment of major depressive disorder. Like vilazodone (Viibryd), another serotonergic...
The FDA has approved vortioxetine (vor" tye ox' e teen; Trintellix – Takeda/Lundbeck), a new serotonergic drug, for treatment of major depressive disorder. Like vilazodone (Viibryd), another serotonergic antidepressant, it has been claimed to have a low incidence of sexual side effects and no significant effect on weight.
Med Lett Drugs Ther. 2013 Nov 25;55(1430):93-5 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • November 1, 2013;  (Issue 135)
The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be...
The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Treat Guidel Med Lett. 2013 Nov;11(135):101-6 | Show Full IntroductionHide Full Introduction

Paroxetine (Brisdelle) for Hot Flashes

   
The Medical Letter on Drugs and Therapeutics • October 28, 2013;  (Issue 1428)
The FDA has approved a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle – Noven Therapeutics) for treatment of moderate-to-severe vasomotor symptoms...
The FDA has approved a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle – Noven Therapeutics) for treatment of moderate-to-severe vasomotor symptoms associated with menopause. It is the first non-hormonal therapy to be approved for this indication. Paroxetine mesylate (Pexeva) and paroxetine hydrochloride (Paxil, and generics) are marketed in higher doses for treatment of depression and other psychiatric disorders.
Med Lett Drugs Ther. 2013 Oct 28;55(1428):85-6 | Show Full IntroductionHide Full Introduction

Citalopram, Escitalopram and the QT Interval

   
The Medical Letter on Drugs and Therapeutics • July 22, 2013;  (Issue 1421)
In 2011, the FDA asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) citalopram (Celexa, and generics) to lower the maximum daily dosage of the drug because of a dose-related...
In 2011, the FDA asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) citalopram (Celexa, and generics) to lower the maximum daily dosage of the drug because of a dose-related increase in the QT interval. Since then, some of our readers have asked whether escitalopram (Lexapro, and generics), the active enantiomer of citalopram, could have the same effect.
Med Lett Drugs Ther. 2013 Jul 22;55(1421):59 | Show Full IntroductionHide Full Introduction

Drugs for Psychiatric Disorders

   
The Medical Letter on Drugs and Therapeutics • June 1, 2013;  (Issue 130)
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many...
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.
Treat Guidel Med Lett. 2013 Jun;11(130):53-64 | Show Full IntroductionHide Full Introduction

Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • April 1, 2013;  (Issue 128)
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Treat Guidel Med Lett. 2013 Apr;11(128):31-42 | Show Full IntroductionHide Full Introduction

In Brief: Budeprion XL 300 Has Been Withdrawn

   
The Medical Letter on Drugs and Therapeutics • October 29, 2012;  (Issue 1402)
The FDA has asked Impax Laboratories/Teva Pharmaceuticals to stop production and distribution of Budeprion XL 300 mg, a generic extended-release formulation of the antidepressant bupropion (Wellbutrin XL),...
The FDA has asked Impax Laboratories/Teva Pharmaceuticals to stop production and distribution of Budeprion XL 300 mg, a generic extended-release formulation of the antidepressant bupropion (Wellbutrin XL), because it has found that Budeprion XL 300 mg releases bupropion more rapidly than Wellbutrin XL 300 mg, the original brand name product. Patients switched from the brand name to the generic formulation have complained for years that the generic was less effective and caused more side effects than the original formulation. In 2007, ConsumerLab.com, an independent laboratory, conducted dissolution testing of Budeprion XL, which uses a matrix for slow release, and Wellbutrin XL, which uses a membrane. According to the test results, the Budeprion XL matrix released more bupropion in the first 4 hours than the Wellbutrin XL membrane did.1 The FDA decided to conduct its own studies of Budeprion XL 300 mg and arrived at a similar conclusion. The original approval of the generic formulation was based on pharmacokinetic tests conducted on 150-mg tablets of the Impax/Teva formulation, with results extrapolated to the 300-mg tablet.

Bupropion is often used as an alternative to a selective serotonin reuptake inhibitor (SSRI) or another antidepressant because it does not cause sexual dysfunction, sedation, or weight gain.2 It is also used as an aid in smoking cessation.3 It is contraindicated in patients at increased risk of seizures (including patients with a history of an eating disorder). Other 300-mg formulations of generic extended-release bupropion have not been associated with post-marketing complaints and continue to be available.

1. Wellbutrin versus generic bupropion. Med Lett Drugs Ther 2008; 50:54.

2. Drugs for depression and bipolar disorder. Treat Guidel Med Lett 2010; 8:35.

3. Drugs for tobacco dependence. Treat Guidel Med Lett 2008; 6:61.

Download complete U.S. English article

Med Lett Drugs Ther. 2012 Oct 29;54(1402):88 | Show Full IntroductionHide Full Introduction

Drugs for Insomnia

   
The Medical Letter on Drugs and Therapeutics • July 1, 2012;  (Issue 119)
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as...
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.
Treat Guidel Med Lett. 2012 Jul;10(119):57-60 | Show Full IntroductionHide Full Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • May 28, 2012;  (Issue 1391)
The primary symptoms of menopause are vasomotor and genitourinary. Vasomotor symptoms ("hot flashes") cause daytime discomfort and chronic insomnia. A thin, dry vaginal lining and thin urethral mucosa can...
The primary symptoms of menopause are vasomotor and genitourinary. Vasomotor symptoms ("hot flashes") cause daytime discomfort and chronic insomnia. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar irritation, pain during intercourse, and an increased risk for urinary tract infection.
Med Lett Drugs Ther. 2012 May 28;54(1391):41-3 | Show Full IntroductionHide Full Introduction

Vilazodone (Viibryd) - A New Antidepressant

   
The Medical Letter on Drugs and Therapeutics • July 11, 2011;  (Issue 1368)
Vilazodone (Viibryd – Forest), a selective serotonin reuptake inhibitor (SSRI) and partial 5-HT1A receptor agonist, has been approved by the FDA for treatment of depression. It has been claimed to have no...
Vilazodone (Viibryd – Forest), a selective serotonin reuptake inhibitor (SSRI) and partial 5-HT1A receptor agonist, has been approved by the FDA for treatment of depression. It has been claimed to have no sexual side effects and not to cause weight gain.
Med Lett Drugs Ther. 2011 Jul 11;53(1368):53-4 | Show Full IntroductionHide Full Introduction

Capsaicin Patch (Qutenza) for Postherpetic Neuralgia

   
The Medical Letter on Drugs and Therapeutics • May 30, 2011;  (Issue 1365)
The FDA has approved a topical 8% patch formulation of capsaicin (Qutenza – NeurogesX), available only by prescription, for local treatment of postherpetic neuralgia. Postherpetic neuralgia occurs after...
The FDA has approved a topical 8% patch formulation of capsaicin (Qutenza – NeurogesX), available only by prescription, for local treatment of postherpetic neuralgia. Postherpetic neuralgia occurs after herpes zoster in about one third of patients ≥60 years old and can persist for months or even years.
Med Lett Drugs Ther. 2011 May 30;53(1365):42-3 | Show Full IntroductionHide Full Introduction

Diet, Drugs and Surgery for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • April 1, 2011;  (Issue 104)
...
Adults with a body mass index (BMI=kg/m2) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.
Treat Guidel Med Lett. 2011 Apr;9(104):17-22 | Show Full IntroductionHide Full Introduction

Extended-Release Trazodone (Oleptro) for Depression

   
The Medical Letter on Drugs and Therapeutics • November 15, 2010;  (Issue 1351)
The FDA has approved the marketing of an extended-release formulation of trazodone (Oleptro – Angelini Labopharm) for treatment of major depressive disorder in adults. Immediate-release trazodone has been...
The FDA has approved the marketing of an extended-release formulation of trazodone (Oleptro – Angelini Labopharm) for treatment of major depressive disorder in adults. Immediate-release trazodone has been available for treatment of depression for many years, but is used mostly in low doses for its sedating effects.
Med Lett Drugs Ther. 2010 Nov 15;52(1351):91-2 | Show Full IntroductionHide Full Introduction

Drugs for Depression and Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • May 1, 2010;  (Issue 93)
Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and...
Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective, poorly tolerated or cannot be used. Some drugs are recommended here for indications that have not been approved by the FDA.
Treat Guidel Med Lett. 2010 May;8(93):35-42 | Show Full IntroductionHide Full Introduction

L-Methylfolate (Deplin) for Depression and Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
L-methylfolate (Deplin — Pamlab) is a “medical food” marketed for adjunctive use in depression or schizophrenia in patients with suboptimal folate levels. It is available only by...
L-methylfolate (Deplin — Pamlab) is a “medical food” marketed for adjunctive use in depression or schizophrenia in patients with suboptimal folate levels. It is available only by prescription.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):31-2 | Show Full IntroductionHide Full Introduction

Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • April 1, 2010;  (Issue 92)
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Treat Guidel Med Lett. 2010 Apr;8(92):25-34 | Show Full IntroductionHide Full Introduction

Duloxetine (Cymbalta) for Fibromyalgia

   
The Medical Letter on Drugs and Therapeutics • July 28, 2008;  (Issue 1291)
Duloxetine (Cymbalta - Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica), which is also approved for treatment of neuropathic pain and epilepsy, was the...
Duloxetine (Cymbalta - Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica), which is also approved for treatment of neuropathic pain and epilepsy, was the first. Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is already marketed for treatment of depression and diabetic neuropathy.
Med Lett Drugs Ther. 2008 Jul 28;50(1291):57 | Show Full IntroductionHide Full Introduction

Wellbutrin Versus Generic Bupropion

   
The Medical Letter on Drugs and Therapeutics • July 14, 2008;  (Issue 1290)
Bupropion (Wellbutrin - GlaxoSmithKline, and others) is a norepinephrine and dopamine reuptake inhibitor that has been a useful antidepressant because, unlike some other antidepressants, it does not cause...
Bupropion (Wellbutrin - GlaxoSmithKline, and others) is a norepinephrine and dopamine reuptake inhibitor that has been a useful antidepressant because, unlike some other antidepressants, it does not cause sexual dysfunction, weight gain or sedation. Some patients who were switched from Wellbutrin to a generic alternative have reported worsening side effects and relapse of previously controlled depressive symptoms.1 Most of the complaints have come from patients switched from Wellbutrin XL 300 mg to the generic 300-mg formulation of extended-release bupropion marketed by Teva (Budeprion XL).2 In 2007, about 1 million prescriptions per month were dispensed for extended-release formulations of bupropion; about 40% of these were written for Budeprion XL 300 mg.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):54-5 | Show Full IntroductionHide Full Introduction

Diet, Drugs and Surgery for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • April 1, 2008;  (Issue 68)
Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing...
Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing weight but are associated with high long-term failure rates. Drugs may help some patients, but all currently available drugs for weight reduction have drawbacks. Gastric surgery can produce marked weight loss in the severely obese, but long-term data on safety are limited.
Treat Guidel Med Lett. 2008 Apr;6(68):23-7 | Show Full IntroductionHide Full Introduction

SSRIs and Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • November 19, 2007;  (Issue 1274)
Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is...
Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is biologically plausible because bone has serotonin receptors, and SSRI-treated mice have reduced bone mass.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):95-6 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • October 1, 2007;  (Issue 62)
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the...
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the bloodbrain barrier.
Treat Guidel Med Lett. 2007 Oct;5(62):89-94 | Show Full IntroductionHide Full Introduction

Pregabalin (Lyrica) for Fibromyalgia

   
The Medical Letter on Drugs and Therapeutics • September 24, 2007;  (Issue 1270)
Pregabalin (Lyrica - Pfizer) is the first drug approved by the FDA for management of fibromyalgia. When it was first marketed, pregabalin, which is structurally similar to gabapentin (Neurontin, and others),...
Pregabalin (Lyrica - Pfizer) is the first drug approved by the FDA for management of fibromyalgia. When it was first marketed, pregabalin, which is structurally similar to gabapentin (Neurontin, and others), was approved for treatment of neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy and for adjunctive treatment of partial onset seizures in adults with epilepsy. It has also been prescribed off-label for other types of neuropathic pain such as sciatica.
Med Lett Drugs Ther. 2007 Sep 24;49(1270):77-9 | Show Full IntroductionHide Full Introduction

Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • April 1, 2007;  (Issue 56)
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants...
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants and anticonvulsants have been used to treat neuropathic pain. Combining two different types of analgesics may nprovide an additive analgesic effect without increasing adverse effects.
Treat Guidel Med Lett. 2007 Apr;5(56):23-32 | Show Full IntroductionHide Full Introduction

Drugs for Psychiatric Disorders

   
The Medical Letter on Drugs and Therapeutics • June 1, 2006;  (Issue 46)
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) is used for many of them as...
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) is used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.
Treat Guidel Med Lett. 2006 Jun;4(46):35-46 | Show Full IntroductionHide Full Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • March 1, 2006;  (Issue 43)
Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort...
Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort and altered bowel habits.
Treat Guidel Med Lett. 2006 Mar;4(43):11-6 | Show Full IntroductionHide Full Introduction

Drugs in the Elderly

   
The Medical Letter on Drugs and Therapeutics • January 16, 2006;  (Issue 1226)
The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse...
The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse effects.
Med Lett Drugs Ther. 2006 Jan 16;48(1226):6-7 | Show Full IntroductionHide Full Introduction

Duloxetine (Cymbalta): A New SNRI for Depression

   
The Medical Letter on Drugs and Therapeutics • October 11, 2004;  (Issue 1193)
Duloxetine hydrochloride (Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), has been approved by the FDA for treatment of major depressive disorder in adults, and more...
Duloxetine hydrochloride (Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), has been approved by the FDA for treatment of major depressive disorder in adults, and more recently for diabetic peripheral neuropathy as well. The Medical Letter will review its role in diabetic neuropathy in a future issue.
Med Lett Drugs Ther. 2004 Oct 11;46(1193):81-3 | Show Full IntroductionHide Full Introduction

Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • July 1, 2004;  (Issue 23)
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of...
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Treat Guidel Med Lett. 2004 Jul;2(23):47-54 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • June 1, 2004;  (Issue 22)
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the...
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the blood-brain barrier.
Treat Guidel Med Lett. 2004 Jun;2(22):41-6 | Show Full IntroductionHide Full Introduction

Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression

   
The Medical Letter on Drugs and Therapeutics • March 15, 2004;  (Issue 1178)
The fixed-dose combination of olanzapine and fluoxetine (Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (Zyprexa), which is...
The fixed-dose combination of olanzapine and fluoxetine (Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (Zyprexa), which is mainly used as an antipsychotic (Medical Letter 2003; 45:102), is FDA-approved for treatment of acute manic episodes and for maintenance treatment of bipolar disorder. Fluoxetine alone (Prozac, and others), which is mainly used as an antidepressant (Medical Letter 2003; 45:93), has no specific approval for use in bipolar disorder.
Med Lett Drugs Ther. 2004 Mar 15;46(1178):23-4 | Show Full IntroductionHide Full Introduction

Is Effexor More Effective than an SSRI?

   
The Medical Letter on Drugs and Therapeutics • February 16, 2004;  (Issue 1176)
Venlafaxine (Effexor, Effexor XR - Wyeth), an antidepressant that inhibits both norepinephrine and serotonin reuptake, was first approved by the FDA in 1993. It has been used mainly as a second-line agent for...
Venlafaxine (Effexor, Effexor XR - Wyeth), an antidepressant that inhibits both norepinephrine and serotonin reuptake, was first approved by the FDA in 1993. It has been used mainly as a second-line agent for patients who have not responded to a selective serotonin reuptake inhibitor (SSRI). Some Medical Letter consultants have had the clinical impression that venlafaxine is more effective than an SSRI, particularly for patients with severe, classic depression (melancholia), and believe it should be considered a first-line drug (Treatment Guidelines from the Medical Letter 2003, 1:69). Is venlafaxine more effective than an SSRI for treatment of depression?
Med Lett Drugs Ther. 2004 Feb 16;46(1176):15-6 | Show Full IntroductionHide Full Introduction

Which SSRI?

   
The Medical Letter on Drugs and Therapeutics • November 24, 2003;  (Issue 1170)
Five different selective serotonin reuptake inhibitors (SSRIs) are promoted for treatment of depression and a sixth (fluvoxamine) for use in obsessive compulsive disorder. Which one should we prescribe for our...
Five different selective serotonin reuptake inhibitors (SSRIs) are promoted for treatment of depression and a sixth (fluvoxamine) for use in obsessive compulsive disorder. Which one should we prescribe for our patients?
Med Lett Drugs Ther. 2003 Nov 24;45(1170):93-5 | Show Full IntroductionHide Full Introduction

Drugs for Psychiatric Disorders

   
The Medical Letter on Drugs and Therapeutics • July 1, 2003;  (Issue 11)
The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and...
The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions, 2003.
Treat Guidel Med Lett. 2003 Jul;1(11):69-76 | Show Full IntroductionHide Full Introduction

Atomoxetine (Strattera) for ADHD

   
The Medical Letter on Drugs and Therapeutics • February 3, 2003;  (Issue 1149)
Atomoxetine (Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not...
Atomoxetine (Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not a controlled substance and is approved for use in adults as well as children. Older non-stimulant drugs that have been used to treat ADHD, although not FDA-approved, include the alpha2-agonist clonidine (Catapres, and others) and the tricyclic antidepressant desipramine (Norpramin, and others) (Medical Letter 1996; 38:109).
Med Lett Drugs Ther. 2003 Feb 3;45(1149):11-2 | Show Full IntroductionHide Full Introduction

Escitalopram (Lexapro) for Depression

   
The Medical Letter on Drugs and Therapeutics • September 30, 2002;  (Issue 1140)
Escitalopram (Lexapro - Forest), the active S-enantiomer of racemic citalopram (Celexa - Forest), a selective serotonin reuptake inhibitor (SSRI), was recently approved by the FDA for treatment of depression....
Escitalopram (Lexapro - Forest), the active S-enantiomer of racemic citalopram (Celexa - Forest), a selective serotonin reuptake inhibitor (SSRI), was recently approved by the FDA for treatment of depression. The manufacturer plans to stop promoting Celexa in favor of Lexapro; Celexa will continue to be available for patients already taking it.
Med Lett Drugs Ther. 2002 Sep 30;44(1140):83-4 | Show Full IntroductionHide Full Introduction

Prozac Weekly

   
The Medical Letter on Drugs and Therapeutics • April 2, 2001;  (Issue 1101)
The FDA has approved a new formulation of fluoxetine for once-weekly maintenance treatment of depression in patients who have responded to daily fluoxetine...
The FDA has approved a new formulation of fluoxetine for once-weekly maintenance treatment of depression in patients who have responded to daily fluoxetine (Prozac).
Med Lett Drugs Ther. 2001 Apr 2;43(1101):27 | Show Full IntroductionHide Full Introduction

Hypnotic Drugs

   
The Medical Letter on Drugs and Therapeutics • August 7, 2000;  (Issue 1084)
Superseded by Drugs of Choice HandbookMany drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be...
Superseded by Drugs of Choice Handbook
Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective than drugs.
Med Lett Drugs Ther. 2000 Aug 7;42(1084):71-2 | Show Full IntroductionHide Full Introduction

Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • June 26, 2000;  (Issue 1081)
Alosetron hydrochloride (Lotronex - Glaxo Welcome), a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is...
Alosetron hydrochloride (Lotronex - Glaxo Welcome), a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is diarrhea.
Med Lett Drugs Ther. 2000 Jun 26;42(1081):53-4 | Show Full IntroductionHide Full Introduction

Amprenavir: A New HIV Protease Inhibitor

   
The Medical Letter on Drugs and Therapeutics • July 16, 1999;  (Issue 1057)
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least...
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Med Lett Drugs Ther. 1999 Jul 16;41(1057):63-6 | Show Full IntroductionHide Full Introduction

Drugs for Depression and Anxiety

   
The Medical Letter on Drugs and Therapeutics • April 9, 1999;  (Issue 1050)
The number of drugs marketed for treatment of depression has increased in recent years. Antidepressants are generally also effective for treatment of...
The number of drugs marketed for treatment of depression has increased in recent years. Antidepressants are generally also effective for treatment of anxiety.
Med Lett Drugs Ther. 1999 Apr 9;41(1050):33-8 | Show Full IntroductionHide Full Introduction

Drugs for Psychiatric Disorders

   
The Medical Letter on Drugs and Therapeutics • April 11, 1997;  (Issue 998)
The number of new drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and...
The number of new drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions, 1997.
Med Lett Drugs Ther. 1997 Apr 11;39(998):33-40 | Show Full IntroductionHide Full Introduction

Mirtazapine - A New Antidepressant

   
The Medical Letter on Drugs and Therapeutics • December 20, 1996;  (Issue 990)
Mirtazapine (mir taz a peen; Remeron - Organon) has been approved by the US Food and Drug Administration for treatment of depression. A tetracyclic piperazinoazepine, it is an analog of mianserin, an...
Mirtazapine (mir taz a peen; Remeron - Organon) has been approved by the US Food and Drug Administration for treatment of depression. A tetracyclic piperazinoazepine, it is an analog of mianserin, an antidepressant available in Europe, but is structurally unrelated to antidepressants previously available in the USA.
Med Lett Drugs Ther. 1996 Dec 20;38(990):113-4 | Show Full IntroductionHide Full Introduction

Clonidine for Treatment of Attention-Deficit/Hyperactivity Disorder

   
The Medical Letter on Drugs and Therapeutics • December 6, 1996;  (Issue 989)
Clonidine, an Alpha2-selective adrenergic agonist marketed in the USA only for treatment of hypertension, has also been used in recent years to treat children with attention-deficit/hyperactivity disorder...
Clonidine, an Alpha2-selective adrenergic agonist marketed in the USA only for treatment of hypertension, has also been used in recent years to treat children with attention-deficit/hyperactivity disorder (ADHD).
Med Lett Drugs Ther. 1996 Dec 6;38(989):109-10 | Show Full IntroductionHide Full Introduction

Hypnotic Drugs

   
The Medical Letter on Drugs and Therapeutics • July 5, 1996;  (Issue 978)
Superseded by Drugs of Choice HandbookInsomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including...
Superseded by Drugs of Choice Handbook
Insomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including five benzodiazepines and zolpidem (Ambien), a non-benzodiazepine that binds to benzodiazepine receptors in the brain. Some drugs marketed for other indications, such as antihistamines, antidepressants and antipsychotics, are also used as hypnotics. For many patients, nonpharmacological treatment of insomnia may be more effective than drugs, especially in the long term (CM Morin et al, Am J Psychiatry, 151:1172, 1994).
Med Lett Drugs Ther. 1996 Jul 5;38(978):59-61 | Show Full IntroductionHide Full Introduction

Nefazodone for Depression

   
The Medical Letter on Drugs and Therapeutics • April 14, 1995;  (Issue 946)
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone...
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
Med Lett Drugs Ther. 1995 Apr 14;37(946):33-5 | Show Full IntroductionHide Full Introduction

Fluvoxamine for Obsessive-Compulsive Disorder

   
The Medical Letter on Drugs and Therapeutics • February 17, 1995;  (Issue 942)
Fluvoxamine (Luvox - Solvay), a selective serotonin reuptake inhibitor (SSRI), has been approved for treatment of obsessive-compulsive disorder (OCD) by the US Food and Drug Administration. Fluoxetine...
Fluvoxamine (Luvox - Solvay), a selective serotonin reuptake inhibitor (SSRI), has been approved for treatment of obsessive-compulsive disorder (OCD) by the US Food and Drug Administration. Fluoxetine (Prozac), another SSRI antidepressant, and clomipramine (Anafranil), a tricyclic antidepressant that also inhibits serotonin reuptake, are the only other drugs available for this indication in the USA. Antidepressants that do not inhibit serotonin reuptake have not been effective for treatment of this condition.
Med Lett Drugs Ther. 1995 Feb 17;37(942):13-4 | Show Full IntroductionHide Full Introduction

Use of Nicotine to Stop Smoking

   
The Medical Letter on Drugs and Therapeutics • January 20, 1995;  (Issue 940)
Many patients ask physicians to help them stop smoking. Since nicotine gum and patches were first marketed (Medical Letter, 26:47, 1984; 34:37, 1992), more data have become available on their effective use,...
Many patients ask physicians to help them stop smoking. Since nicotine gum and patches were first marketed (Medical Letter, 26:47, 1984; 34:37, 1992), more data have become available on their effective use, and new formulations of the drug have been developed. Because of its slower rate of absorption, nicotine from gum or patches does not produce the pleasure some people associate with cigarette smoking, but it can relieve the irritability, difficulty in concentrating and other symptoms that occur after withdrawal from smoking.
Med Lett Drugs Ther. 1995 Jan 20;37(940):6-8 | Show Full IntroductionHide Full Introduction

Venlafaxine - A New Antidepressant

   
The Medical Letter on Drugs and Therapeutics • June 10, 1994;  (Issue 924)
Venlafaxine hydrochloride (Effexor - Wyeth-Ayerst) was recently approved by the US Food and Drug Administration for treatment of depression. An aminomethyl-benzyl- cyclohexanol, it is chemically related to...
Venlafaxine hydrochloride (Effexor - Wyeth-Ayerst) was recently approved by the US Food and Drug Administration for treatment of depression. An aminomethyl-benzyl- cyclohexanol, it is chemically related to bupropion (Wellbutrin).
Med Lett Drugs Ther. 1994 Jun 10;36(924):49-50 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • April 16, 1993;  (Issue 894)
Approaches to treatment of Parkinson's disease have changed in recent years. Previously, the only goal was to treat symptoms with levodopa or other drugs. A new approach is to try to slow progression of the...
Approaches to treatment of Parkinson's disease have changed in recent years. Previously, the only goal was to treat symptoms with levodopa or other drugs. A new approach is to try to slow progression of the disease. (This issue is superseded by 1999 Drugs of Choice.)
Med Lett Drugs Ther. 1993 Apr 16;35(894):31-4 | Show Full IntroductionHide Full Introduction

Sotalol for Cardiac Arrhythmias

   
The Medical Letter on Drugs and Therapeutics • April 2, 1993;  (Issue 893)
Sotalol (hydrochloride (Betapace -Berlex; Sotacor -Bristol Laboratories of Canada), an antiarrhythmic drug that prolongs repolarization (Class III) and also has beta-adrenergic-blocking activity (Class II),...
Sotalol (hydrochloride (Betapace -Berlex; Sotacor -Bristol Laboratories of Canada), an antiarrhythmic drug that prolongs repolarization (Class III) and also has beta-adrenergic-blocking activity (Class II), was recently approved by the US Food and Drug Administration (FDA) for oral treatment of life-threatening ventricular arrhythmias.
Med Lett Drugs Ther. 1993 Apr 2;35(893):27-8 | Show Full IntroductionHide Full Introduction

Atovaquone for Pneumocystis Carinii Pneumonia

   
The Medical Letter on Drugs and Therapeutics • April 2, 1993;  (Issue 893)
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP)...
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who cannot tolerate trimethoprim-sulfamethoxazole (Septra, Bactrim, and others). PCP is a common opportunistic infection and frequent cause of death in patients with AIDS.
Med Lett Drugs Ther. 1993 Apr 2;35(893):28-9 | Show Full IntroductionHide Full Introduction

Paroxetine for Treatment of Depression

   
The Medical Letter on Drugs and Therapeutics • March 19, 1993;  (Issue 892)
Paroxetine (Paxil - SmithKline Beecham), a new selective serotonin reuptake inhibitor (SSRI), is now available in the USA. Two other SSRIs, fluoxetine (Prozac - Medical Letter, 30:45, 1988; 32:83, 1990) and...
Paroxetine (Paxil - SmithKline Beecham), a new selective serotonin reuptake inhibitor (SSRI), is now available in the USA. Two other SSRIs, fluoxetine (Prozac - Medical Letter, 30:45, 1988; 32:83, 1990) and sertraline (Zoloft - Medical Letter, 34:47, 1992), were approved previously.
Med Lett Drugs Ther. 1993 Mar 19;35(892):24-5 | Show Full IntroductionHide Full Introduction

Choice of an Antidepressant

   
The Medical Letter on Drugs and Therapeutics • March 19, 1993;  (Issue 892)
Since the introduction of fluoxetine (Prozac - Medical Letter, 30:45, 1988), bupropion (Wellbutrin - Medical Letter, 31:97, 1989), sertraline (Zoloft - Medical Letter, 34:47, 1992) and paroxetine (Paxil -...
Since the introduction of fluoxetine (Prozac - Medical Letter, 30:45, 1988), bupropion (Wellbutrin - Medical Letter, 31:97, 1989), sertraline (Zoloft - Medical Letter, 34:47, 1992) and paroxetine (Paxil - this issue), the choice of an antidepressant has become more difficult. Should these widely prescribed new drugs replace tricyclic antidepressants such as amitriptyline (Elavil, and others), imipramine (Tofranil, and others), or nortriptyline (Aventyl, and others) for treatment of most patients with depression?
Med Lett Drugs Ther. 1993 Mar 19;35(892):25-6 | Show Full IntroductionHide Full Introduction

Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • January 8, 1993;  (Issue 887)
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as...
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. (American Pain Society, Principles of analgesic Use, 3rd ed, Skokie, illinois: American pain society, 1992).
Med Lett Drugs Ther. 1993 Jan 8;35(887):1-6 | Show Full IntroductionHide Full Introduction

Flumazenil

   
The Medical Letter on Drugs and Therapeutics • July 10, 1992;  (Issue 874)
Flumazenil (Mazicon - Roche), a benzodiazepine receptor antagonist, has been approved by the US Food and Drug Administration to reverse the sedative effects of benzodiazepines after anesthesia, sedation for...
Flumazenil (Mazicon - Roche), a benzodiazepine receptor antagonist, has been approved by the US Food and Drug Administration to reverse the sedative effects of benzodiazepines after anesthesia, sedation for brief surgical or diagnostic procedures, or after benzodiazepine overdosage. The drug does not antagonize opioids, non-benzodiazepine sedatives, or anesthetic drugs.
Med Lett Drugs Ther. 1992 Jul 10;34(874):66-8 | Show Full IntroductionHide Full Introduction

Sertraline For Treatment Of Depression

   
The Medical Letter on Drugs and Therapeutics • May 15, 1992;  (Issue 870)
Sertraline (Zoloft - Roerig), a serotonin reuptake inhibitor, was recently approved for marketing by the US Food and Drug Administration for treatment of depression. Another serotonin reuptake inhibitor,...
Sertraline (Zoloft - Roerig), a serotonin reuptake inhibitor, was recently approved for marketing by the US Food and Drug Administration for treatment of depression. Another serotonin reuptake inhibitor, fluoxetine (Prozac), is prescribed more frequently in the USA than any other antidepressant (Medical Letter, 32:83, 1990).
Med Lett Drugs Ther. 1992 May 15;34(870):47-8 | Show Full IntroductionHide Full Introduction

Alprazolam For Panic Disorder

   
The Medical Letter on Drugs and Therapeutics • April 5, 1991;  (Issue 841)
Alprazolam (Xanax - Upjohn), a triazolobenzodiazepine previously available in the USA for treatment of anxiety (Medical Letter 24:41, 1982), was recently approved by the US Food and Drug Administration (FDA)...
Alprazolam (Xanax - Upjohn), a triazolobenzodiazepine previously available in the USA for treatment of anxiety (Medical Letter 24:41, 1982), was recently approved by the US Food and Drug Administration (FDA) for treatment of panic disorder, with or without agoraphobia. According to one report, alprazolam was the fifth most widely prescribed drug in the USA last year (American Medical News, March 4, 1991, page 4).
Med Lett Drugs Ther. 1991 Apr 5;33(841):30-1 | Show Full IntroductionHide Full Introduction

Fluoxetine (Prozac) Revisited

   
The Medical Letter on Drugs and Therapeutics • September 7, 1990;  (Issue 826)
In the short time since fluoxetine (Prozac - Lilly) first became available in the USA (Medical Letter, 30:45, 1988), it has become the most frequently prescribed of all antidepressants. Some recent reports,...
In the short time since fluoxetine (Prozac - Lilly) first became available in the USA (Medical Letter, 30:45, 1988), it has become the most frequently prescribed of all antidepressants. Some recent reports, however, have questioned its safety.
Med Lett Drugs Ther. 1990 Sep 7;32(826):83-4 | Show Full IntroductionHide Full Introduction

Sudden Death in children A Tricyclic Antidepressant

   
The Medical Letter on Drugs and Therapeutics • June 1, 1990;  (Issue 819)
The 1990 labeling for Norpramin, the Merrell Dow brand of the tricyclic antidepressant desipramine, reports the occurrence of sudden death in an eight-year-old child treated with the drug. Desipramine is also...
The 1990 labeling for Norpramin, the Merrell Dow brand of the tricyclic antidepressant desipramine, reports the occurrence of sudden death in an eight-year-old child treated with the drug. Desipramine is also available as Pertofrane (Rorer) and generically.
Med Lett Drugs Ther. 1990 Jun 1;32(819):53 | Show Full IntroductionHide Full Introduction

Bupropion For Depression

   
The Medical Letter on Drugs and Therapeutics • November 3, 1989;  (Issue 804)
Bupropion (Wellbutrin - Burroughs Wellcome) was recently marketed in the USA for treatment of depression. First approved by the Food and Drug Administration in late 1985, the drug was withdrawn from the...
Bupropion (Wellbutrin - Burroughs Wellcome) was recently marketed in the USA for treatment of depression. First approved by the Food and Drug Administration in late 1985, the drug was withdrawn from the market in early 1986 because of a high incidence of seizures in one study.
Med Lett Drugs Ther. 1989 Nov 3;31(804):97-8 | Show Full IntroductionHide Full Introduction

Oral Hypnotic Drugs

   
The Medical Letter on Drugs and Therapeutics • March 10, 1989;  (Issue 787)
Three benzodiazepines and 16 other compounds are marketed in the USA for treatment of insomnia. Many authorities believe that insomnia is overdiagnosed and overtreated (MK Erman, ed, Sleep Disorders,...
Three benzodiazepines and 16 other compounds are marketed in the USA for treatment of insomnia. Many authorities believe that insomnia is overdiagnosed and overtreated (MK Erman, ed, Sleep Disorders, Psychiatr Clin North Am, Volume 10, Dec 1987).
Med Lett Drugs Ther. 1989 Mar 10;31(787):23-4 | Show Full IntroductionHide Full Introduction

Foods Interacting With MAO Inhibitors

   
The Medical Letter on Drugs and Therapeutics • February 10, 1989;  (Issue 785)
Many fermented foods contain tyramine as a byproduct formed by the bacterial breakdown of the amino acid tyrosine; it can also be formed by para-hydroxylation of phenylethylamine or dehydroxylation of DOPA and...
Many fermented foods contain tyramine as a byproduct formed by the bacterial breakdown of the amino acid tyrosine; it can also be formed by para-hydroxylation of phenylethylamine or dehydroxylation of DOPA and dopamine. Tyramine and some other amines found in food can cause hypertensive reactions in patients taking monoamine oxidase (MAO)inhibitors.
Med Lett Drugs Ther. 1989 Feb 10;31(785):11-2 | Show Full IntroductionHide Full Introduction

Drugs for Parkinsonism

   
The Medical Letter on Drugs and Therapeutics • December 16, 1988;  (Issue 781)
Patients with Parkinson's disease have a deficiency of the neurotransmitter dopamine, a catecholamine. Dpamine itself cannot be used to treat the disease because it does not cross the blood-brain barrier, but...
Patients with Parkinson's disease have a deficiency of the neurotransmitter dopamine, a catecholamine. Dpamine itself cannot be used to treat the disease because it does not cross the blood-brain barrier, but its metabolic precursor, levodopa, does cross into the brain and is converted to dopamine by a decarboxylase present both in the brain and in the intestinal tract (JM Cedarbaum, Clin Pharmacokinet, 13:141, 1987).
Med Lett Drugs Ther. 1988 Dec 16;30(781):113-6 | Show Full IntroductionHide Full Introduction

Clomipramine for Obsessive Compulsive Disorder

   
The Medical Letter on Drugs and Therapeutics • November 4, 1988;  (Issue 778)
Clomipramine (Anafranil - Ciba-Geigy), a tricyclic antidepressant, is now available for treatment of obsessive compulsive disorder (OCD) in accordance with the new US Food and Drug Administration (FDA)...
Clomipramine (Anafranil - Ciba-Geigy), a tricyclic antidepressant, is now available for treatment of obsessive compulsive disorder (OCD) in accordance with the new US Food and Drug Administration (FDA) procedure for promising investigational drugs (FE Young et al, JAMA, 259:2267, 1988). In other countries, clomipramine has been widely used for many years for treatment of depression.
Med Lett Drugs Ther. 1988 Nov 4;30(778):102-4 | Show Full IntroductionHide Full Introduction

Treatment of Xerostomia

   
The Medical Letter on Drugs and Therapeutics • July 29, 1988;  (Issue 771)
Xerostomia, dry mouth due to decreased or absent saliva, is a common problem, particularly among elderly patients. Decreased salivary flow can be due to many different conditions, including drug therapy, Sj...
Xerostomia, dry mouth due to decreased or absent saliva, is a common problem, particularly among elderly patients. Decreased salivary flow can be due to many different conditions, including drug therapy, Sj gren's syndrome (keratoconjunctivitis sicca) or radiation of the salivary glands.
Med Lett Drugs Ther. 1988 Jul 29;30(771):74-6 | Show Full IntroductionHide Full Introduction

Fluoxetine For Depression

   
The Medical Letter on Drugs and Therapeutics • April 22, 1988;  (Issue 764)
Fluoxetine (Prozac - Dista), a phenylpropylamide, is the first serotonin-reuptake blocker introduced in the USA for treatment of . It is being promoted as causing fewer adverse effects than other...
Fluoxetine (Prozac - Dista), a phenylpropylamide, is the first serotonin-reuptake blocker introduced in the USA for treatment of . It is being promoted as causing fewer adverse effects than other antidepressants. Claims of greater safety and patient tolerability have often been made for new non-tricyclic antidepressants in recent years, but unpredicted adverse effects have emerged with widespread use, including priapism with trazodone (Desyrel - Medical Letter, 26:35, 1984) and fatal hemolytic anemia with nomifensine (Merital - Medical Letter, 27:73, 1985).
Med Lett Drugs Ther. 1988 Apr 22;30(764):45-7 | Show Full IntroductionHide Full Introduction

Choice of Benzodiazepines

   
The Medical Letter on Drugs and Therapeutics • February 26, 1988;  (Issue 760)
Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the...
Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the benzodiazepines available for oral use in the USA are listed in the table on page 28.
Med Lett Drugs Ther. 1988 Feb 26;30(760):26-8 | Show Full IntroductionHide Full Introduction